CDK2 Human shRNA Plasmid Kit (Locus ID 1017)
CAT#: TL320291
CDK2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 5,740.00
Cited in 1 publication. |
Product images
CNY 1,999.00
CNY 2,700.00
CNY 4,070.00
Specifications
Product Data | |
Product Name | CDK2 Human shRNA Plasmid Kit (Locus ID 1017) |
Locus ID | 1017 |
UniProt ID | P24941 |
Synonyms | CDKN2; p33(CDK2) |
Vector | pGFP-C-shLenti |
Format | Lentiviral plasmids |
Kit Components | CDK2 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 1017). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free. |
RefSeq | NM_001290230, NM_001798, NM_052827, NM_001798.1, NM_001798.2, NM_001798.3, NM_001798.4, NM_052827.1, NM_052827.2, NM_052827.3, NM_001290230.1, BC003065, BC003065.2, NM_001798.5, NM_001290230.2 |
Summary | This gene encodes a member of a family of serine/threonine protein kinases that participate in cell cycle regulation. The encoded protein is the catalytic subunit of the cyclin-dependent protein kinase complex, which regulates progression through the cell cycle. Activity of this protein is especially critical during the G1 to S phase transition. This protein associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2014] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Cyclin-Dependent Kinase 2 Promotes Tumor Proliferation and Induces Radio Resistance in Glioblastoma
,Wang, J;Yang, T;Xu, G;Liu, H;Ren, C;Xie, W;Wang, M;,
Transl Oncol
,PubMed ID 27863310
[CDK2]
|
Documents
Product Manuals |
FAQs |
SDS |